Anti-human vista antibodies and use thereof

Patent metadata

Field	Value
Publication number	US-11649283-B2
Application number	US-201715488351-A
Country	US
Kind code	B2
Filing date	Apr 14, 2017
Priority date	Apr 15, 2016
Publication date	May 16, 2023
Grant date	May 16, 2023

Abstract

The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

First claim

The invention claimed is:

1. An agonistic antibody comprising an antigen binding region that specifically binds to human V-domain Ig Suppressor of T cell Activation (human VISTA), wherein (i) the antibody or antibody fragment agonizes or promotes the effect of VISTA on T cell immunity, wherein said antibody is selected from the following:
(i) one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:200, 201 and 202 and comprising a light chain comprising the V L CDRs of SEQ ID NO:203, 204 and 205;
(ii) one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:380, 381 and 382 and comprising a light chain comprising the V L CDRs of SEQ ID NO:383, 384 and 385;
(iii) one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:470, 471 and 472 and comprising a light chain comprising the V L CDRs of SEQ ID NO:473, 474 and 475;
(iv) one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:500, 501 and 502 and the VL CDR polypeptides of SEQ ID NO:503, 504 and 505;

and wherein the antibody of any of (i) to (iv) comprises a human IgG2 constant or Fc region.

2. The agonist antibody of claim 1 , wherein the human IgG2 constant or Fc region binds to Fc gamma receptors including human CD32A.

3. The agonist antibody claim 1 which is chimeric, human or humanized.

4. The antibody or antibody fragment of claim 1 which:
for embodiment (i) the antibody comprises the VH polypeptide of SEQ ID NO:206 and the VL polypeptide of SEQ ID NO:208;
for embodiment (ii) the antibody comprises the VH polypeptide of SEQ ID NO:386 and the VL polypeptide of SEQ ID NO:388;
for embodiment (iii) the antibody comprises the VH polypeptide of SEQ ID NO:476 and the VL polypeptide of SEQ ID NO:478; or
for embodiment (iv) the antibody comprises the VH polypeptide of SEQ ID NO:506 and the VL polypeptide of SEQ ID NO:508.

5. The antibody of claim 1 , which comprises a human IgG2 constant domain wherein at least one cysteine residue is deleted or changed to another amino acid.

6. A pharmaceutical or diagnostic composition comprising at least one agonistic antibody according to claim 1 .

7. A pharmaceutical comprising at least agonistic antibody according to claim 2 .

8. A pharmaceutical comprising at least agonistic antibody according to claim 3 .

9. A pharmaceutical comprising at least agonistic antibody according to claim 4 .

10. A pharmaceutical comprising at least agonistic antibody according to claim 5 .

11. The agonistic antibody of claim 1 , which is one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:200, 201 and 202 and comprising a light chain comprising the V L CDRs of SEQ ID NO:203, 204 and 205.

12. The agonistic antibody of claim 1 , which is one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:380, 381 and 382 and comprising a light chain comprising the V L CDRs of SEQ ID NO:383, 384 and 385.

13. The agonistic antibody of claim 1 , which is one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:470, 471 and 472 and comprising a light chain comprising the V L CDRs of SEQ ID NO:473, 474 and 475.

14. The agonistic antibody of claim 1 , which is one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:500, 501 and 502 and the VL CDR polypeptides of SEQ ID NO:503, 504 and 505.

15. A pharmaceutical comprising at least agonistic antibody according to claim 11 .

16. A pharmaceutical comprising at least agonistic antibody according to claim 12 .

17. A pharmaceutical comprising at least agonistic antibody according to claim 13 .

18. A pharmaceutical comprising at least agonistic antibody according to claim 14 .

19. An antibody or antibody fragment comprising an antigen binding region that specifically binds to human V-domain Ig Suppressor of T cell Activation (human VISTA), wherein said antibody or antibody fragment is selected from the following:
(i) one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:200, 201 and 202 and comprising a light chain comprising the V L CDRs of SEQ ID NO:203, 204 and 205;
(ii) one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:380, 381 and 382 and comprising a light chain comprising the V L CDRs of SEQ ID NO:383, 384 and 385;
(iii) one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:470, 471 and 472 and comprising a light chain comprising the V L CDRs of SEQ ID NO:473, 474 and 475;
(iv) one comprising a heavy chain comprising the V H CDRs of SEQ ID NO:500, 501 and 502 and the VL CDR polypeptides of SEQ ID NO:503, 504 and 505.

20. The antibody or antibody fragment of any of embodiments (i) to (iv) recited in claim 19 , which comprises a human IgG1, IgG3 or IgG4 constant or Fc region.

21. The antibody or antibody fragment of claim 20 , wherein said a human IgG1, IgG3 or IgG4 constant or Fc region comprises a modification which impairs FcR or complement binding.

22. The antibody or antibody fragment of claim 19 which:
for embodiment (i) the antibody comprises the VH polypeptide of SEQ ID NO:206 and the VL polypeptide of SEQ ID NO:208;
for embodiment (ii) the antibody comprises the VH polypeptide of SEQ ID NO:386 and the VL polypeptide of SEQ ID NO:388;
for embodiment (iii) the antibody comprises the VH polypeptide of SEQ ID NO:476 and the VL polypeptide of SEQ ID NO:478; or
for embodiment (iv) the antibody comprises the VH polypeptide of SEQ ID NO:506 and the VL polypeptide of SEQ ID NO:508.

23. The antibody or antibody fragment of any of embodiments (i) to (iv) recited in claim 22 , which comprises a human IgG1, IgG3 or IgG4 constant or Fc region.

24. The antibody or antibody fragment of claim 23 , wherein said a human IgG1, IgG3 or IgG4 constant or Fc region comprises a modification which impairs FcR or complement binding.

Assignees

• Immunext Inc
• Janssen Pharmaceuticals Inc

Inventors

• Molloy Michael
• Rothstein Jay
• Pechenick Dov
• Snyder Linda
• Powers Gordon

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61K38/16 Primary

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title

• C07K14/705

  Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title

• C07K16/42

  against immunoglobulins · CPC title

• C07K16/46

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title